Osimertinib
- OralOsimertinibTagrissoMay be used in patients with T790M mutations which would otherwise confer resistance to other generations of EGFR inhibitors
- Mechanism of Action
- Inhibits epidermal growth factor receptor (EGFR), a transmembrane amino acid receptor tyrosine kinase found in approximately 15% of non small cell lung cancers.
- EGFR mutations affect downstream signalling pathways resulting in cell proliferation
- Inhibition of these receptors disrupts this proliferation pathway.
Clinical Use
Indications
- Advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutation
- Adverse Effects
- Acneiform rash
- Diarrhoea
- Ocular changes
- Alopecia
- Nail changes
- Interstitial lung disease